Nutrition, metabolism, and cardiovascular diseases : NMCD · 2025
Omega-3 fatty acids and cardiovascular risk-related metabolic markers in diverse populations: a meta-analysis of randomized trials.
СтатьяМетаанализСистематический обзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Chen, Li Xuan, Yan Hongli, Liu Junyan, Cao Yuhang, Zhao Hongjiao, Liu Shixin, Wang Yilin, Sun Yifei, Jia Beili, Yuan Junhua
Аннотация
AIM: Many studies reported the effects of n-3 polyunsaturated fatty acids (PUFA) towards cardiovascular risk, but results are inconclusive. This meta-analysis systemically explored PUFA-mediated effects on representative cardiovascular-related metabolic markers, including glycolipid profile, adiponectin, and oxidative stress indicators in different people.
DATA SYNTHESIS: Literature search on PubMed, EMBASE, Web of Science, and the Cochrane Library were performed up to October 11, 2024. Randomized controlled trials focusing on the effects of n-3 PUFA supplementation on triacylglycerol (TG), low-density lipoprotein (LDL), high-density lipoprotein (HDL), total cholesterol (TC), apolipoprotein, adipokine, hemoglobin A1c (HbA1c), c-reactive protein (CRP), and oxidative stress biomarkers were chosen as outcome variables. There were 24 studies with 2043 subjects showed significant effects: (1)TG decreased by 16.95 mg/dl (21 trials, n = 1491; 95 % CI: 23.25, -10.66), (2)HDL increased by 1.55 mg/dl (22 trials, n = 1914; 95 % CI: 0.69, 2.42), (3)adiponectin increased by 0.96 μg/ml (3 trials, n = 198; 95 % CI: 0.03, 1.8), (4)HbA1c decreased by 0.17 % (3 trials, n = 283; 95 % CI: 0.29, -0.04), (5)LDL decreased by 10.98 mg/dl in women (4 trials, n = 236; 95 % CI: 19.41, -2.5) and by 13.77 mg/dl in the polycystic ovary syndrome (PCOS) (3 trials, n = 180; 95 % CI: 22.83, -4.7), (6)TC decreased by 15.58 mg/dl in women (4 trials, n = 236; 95 % CI: 24.64, -6.53).
CONCLUSIONS: The meta-analysis indicates that n-3 PUFAs improve cardiovascular-related metabolic markers, potentially benefit cardiovascular health in patients with cardiovascular disease, PCOS, and kidney disease, especially in older women via reducing TG and HbA1c and increasing HDL and adiponectin.
DATA SYNTHESIS: Literature search on PubMed, EMBASE, Web of Science, and the Cochrane Library were performed up to October 11, 2024. Randomized controlled trials focusing on the effects of n-3 PUFA supplementation on triacylglycerol (TG), low-density lipoprotein (LDL), high-density lipoprotein (HDL), total cholesterol (TC), apolipoprotein, adipokine, hemoglobin A1c (HbA1c), c-reactive protein (CRP), and oxidative stress biomarkers were chosen as outcome variables. There were 24 studies with 2043 subjects showed significant effects: (1)TG decreased by 16.95 mg/dl (21 trials, n = 1491; 95 % CI: 23.25, -10.66), (2)HDL increased by 1.55 mg/dl (22 trials, n = 1914; 95 % CI: 0.69, 2.42), (3)adiponectin increased by 0.96 μg/ml (3 trials, n = 198; 95 % CI: 0.03, 1.8), (4)HbA1c decreased by 0.17 % (3 trials, n = 283; 95 % CI: 0.29, -0.04), (5)LDL decreased by 10.98 mg/dl in women (4 trials, n = 236; 95 % CI: 19.41, -2.5) and by 13.77 mg/dl in the polycystic ovary syndrome (PCOS) (3 trials, n = 180; 95 % CI: 22.83, -4.7), (6)TC decreased by 15.58 mg/dl in women (4 trials, n = 236; 95 % CI: 24.64, -6.53).
CONCLUSIONS: The meta-analysis indicates that n-3 PUFAs improve cardiovascular-related metabolic markers, potentially benefit cardiovascular health in patients with cardiovascular disease, PCOS, and kidney disease, especially in older women via reducing TG and HbA1c and increasing HDL and adiponectin.